Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences develops proprietary oncology drugs built around its Phospholipid Drug Conjugate™ (PDC) delivery platform. News about CLRB commonly centers on targeted radiotherapeutic programs, including iopofosine I 131 for Waldenström macroglobulinemia and CLR 121125, also called CLR 125, an iodine-125 Auger-emitting program for solid tumors such as triple negative breast, lung and colorectal cancers.
Company updates also cover clinical data from the CLOVER WaM study, oncology conference presentations, European and U.S. regulatory interactions, intellectual property protection, securities financings, and periodic financial results with corporate updates. The recurring disclosures reflect a late-stage clinical biopharmaceutical company funding and advancing cancer-cell-targeting treatments through internal development and research collaborations.
Cellectar Biosciences (NASDAQ: CLRB) reported publication of a Phase 1 dose-escalation study of iopofosine I 131 plus low-dose dexamethasone in 31 heavily pretreated relapsed/refractory multiple myeloma patients in the peer-reviewed journal Cancers.
Among 26 efficacy-evaluable patients, 84.6% achieved stable disease or better. The overall response rate (ORR) was 15.4%, including four partial responses, and a subgroup of evaluable patients (n=10) receiving at least 60 mCi showed a 30% ORR. Investigators described a favorable, manageable safety profile, with adverse events mainly predictable, reversible hematologic toxicities and generally low-grade non-hematologic events, and no new safety signals. According to Cellectar, these findings support continued development of iopofosine I 131 as a novel targeted radiotherapeutic across multiple B‑cell malignancies and suggest potential for repeat dosing strategies.
Cellectar Biosciences (NASDAQ: CLRB) reported new Phase 2b CLOVER WaM data for iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia patients treated immediately after BTK inhibitor therapy (n=24). Outcomes included 100% clinical benefit, 87.5% overall response, 79.2% major response, and median duration of response of 16 months, with 20% exceeding 30 months.
The treatment showed a manageable safety profile, with cytopenias as the only Grade ≥3 adverse event. Based on these results, Cellectar plans to pursue U.S. accelerated approval and initiate a Phase 3 confirmatory trial in 4Q26.
Cellectar Biosciences (NASDAQ: CLRB) reported first quarter 2026 results and corporate updates. The company highlighted positive 12‑month follow-up data from the Phase 2b CLOVER-WaM study of iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia and plans for a Phase 3 confirmatory trial and U.S. FDA accelerated approval filing.
Cellectar completed an oversubscribed financing of up to $140 million to fund development and reported Q1 2026 cash of $8.3 million, R&D expenses of $3.0 million, G&A expenses of $2.8 million, and net loss of $5.7 million.
Cellectar Biosciences (NASDAQ: CLRB) will report first quarter 2026 financial results and provide a corporate update on Thursday, May 14, 2026, at 8:30 a.m. Eastern Time.
The company will host a conference call and webcast, with a replay available on its investor relations website.
Cellectar Biosciences (NASDAQ: CLRB) reported 12-month follow-up results from its Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia. Key results in the per-protocol population (n=55): ORR 83.6%, MRR 61.8%, median DoR 17.8 months, median PFS 13.5 months, and DCR 98.2%.
The dataset meets the FDA-requested ≥12-month follow-up, the company plans a confirmatory trial in 4Q26, and an oversubscribed financing of up to $140 million was announced to support the program.
Cellectar Biosciences (NASDAQ: CLRB) announced an oversubscribed financing of up to $140 million—approximately $35 million upfront and $105 million in milestone-based securities—led by Nantahala Capital. Funding supports a planned global confirmatory pivotal study in Q4 2026, an NDA filing for accelerated approval of iopofosine I 131 in Waldenström macroglobulinemia, advancement of CLR 125, and adds Andrew Gu (Nantahala) to the board.
Cellectar Biosciences (NASDAQ: CLRB) announced acceptance of a poster on CLOVER WaM subset data for relapsed/refractory Waldenström macroglobulinemia (r/r WM) to be presented at ASCO 2026 in Chicago.
The poster (No. 592) titled “Iopofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety” will be presented by Jarrod Longcor on June 1, 2026, 9:00 AM–12:00 PM CDT and highlights efficacy and safety results for patients treated immediately after BTK inhibitor therapy.
Cellectar (NASDAQ: CLRB) enrolled the first patient in a Phase 1b trial of CLR 125 for relapsed or refractory triple negative breast cancer (TNBC) on April 14, 2026. The open-label, dose-escalation study will test three dose regimens and image tumor uptake to inform a recommended Phase 2 dose.
Preclinical data showed selective tumor uptake and no observed end-organ or hematologic toxicity at evaluated doses; additional sites are planned to activate in Q2 with dosimetry, safety, and efficacy updates during 2026.
Cellectar (NASDAQ: CLRB) reported 2025 results and corporate updates on March 4, 2026, highlighting regulatory progress for iopofosine I-131, initiation of a Phase 1b study for CLR 125 in triple negative breast cancer, and patent and supply agreements to support its radiotherapeutic pipeline.
Financials: cash of $13.2M at year-end; full-year net loss of $21.8M; R&D and G&A both ~$11.5M.
Cellectar Biosciences (NASDAQ: CLRB) will report full year financial results for the period ended December 31, 2025, and host a corporate update and conference call on Wednesday, March 4, 2026 at 8:30 a.m. Eastern Time.
The event will be accessible by toll-free dial-in and webcast; a replay of the presentation will be available on the company’s Investor Relations Events page.